JP2004528332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004528332A5 JP2004528332A5 JP2002582954A JP2002582954A JP2004528332A5 JP 2004528332 A5 JP2004528332 A5 JP 2004528332A5 JP 2002582954 A JP2002582954 A JP 2002582954A JP 2002582954 A JP2002582954 A JP 2002582954A JP 2004528332 A5 JP2004528332 A5 JP 2004528332A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polymer
- uric acid
- crosslinking agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 229920000642 polymer Polymers 0.000 claims 21
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 13
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 13
- 229940116269 uric acid Drugs 0.000 claims 13
- 239000003431 cross linking reagent Substances 0.000 claims 12
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 4
- 239000000178 monomer Substances 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical group C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 claims 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical group [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical group [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 2
- 150000001336 alkenes Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical group [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical group NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 claims 2
- 150000007942 carboxylates Chemical group 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 2
- 239000012990 dithiocarbamate Chemical group 0.000 claims 2
- 229920001519 homopolymer Polymers 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Chemical group CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical group [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 claims 2
- 229940031826 phenolate Drugs 0.000 claims 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 2
- 229920000083 poly(allylamine) Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 206010051364 Hyperuricosuria Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 206010046337 Urate nephropathy Diseases 0.000 claims 1
- 201000001509 acute urate nephropathy Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000019808 uric acid nephrolithiasis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28444501P | 2001-04-18 | 2001-04-18 | |
| US30556701P | 2001-07-13 | 2001-07-13 | |
| PCT/US2002/011492 WO2002085381A1 (en) | 2001-04-18 | 2002-04-10 | Method for treating gout and binding uric acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004528332A JP2004528332A (ja) | 2004-09-16 |
| JP2004528332A5 true JP2004528332A5 (https=) | 2005-12-22 |
Family
ID=26962624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002582954A Pending JP2004528332A (ja) | 2001-04-18 | 2002-04-10 | 痛風を治療する方法および尿酸を結合する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20030039627A1 (https=) |
| EP (1) | EP1416942B1 (https=) |
| JP (1) | JP2004528332A (https=) |
| AT (1) | ATE380553T1 (https=) |
| BR (1) | BR0209133A (https=) |
| CA (1) | CA2444347A1 (https=) |
| DE (1) | DE60224052T2 (https=) |
| MX (1) | MXPA03009571A (https=) |
| WO (1) | WO2002085381A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| US7220406B2 (en) * | 2002-10-22 | 2007-05-22 | Genzyme Corporation | Method for promoting bone formation |
| WO2004099288A1 (en) * | 2003-05-09 | 2004-11-18 | Carlsberg A/S | Polyethyleneimine polymers |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7335795B2 (en) * | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7767768B2 (en) * | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| WO2006072054A1 (en) * | 2004-12-30 | 2006-07-06 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
| EP1883405A4 (en) * | 2005-05-09 | 2010-01-27 | Takeda Pharmaceuticals North A | METHODS OF TREATING NEPHROLITHIASIS |
| US8986669B2 (en) * | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| EP3000460A1 (en) | 2005-09-15 | 2016-03-30 | Genzyme Corporation | Sachet formulation for amine polymers |
| EP1945196A2 (en) * | 2005-11-08 | 2008-07-23 | Genzyme Corporation | Magnesium-containing polymers for hyperphosphatemia |
| EP2016114A2 (en) * | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
| WO2008005217A2 (en) * | 2006-07-05 | 2008-01-10 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
| AU2007275711A1 (en) * | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
| EP2066293A2 (en) | 2006-09-29 | 2009-06-10 | Genzyme Corporation | Amide dendrimer compositions |
| KR20150024919A (ko) * | 2006-11-13 | 2015-03-09 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 |
| US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| US8163799B2 (en) * | 2006-12-14 | 2012-04-24 | Genzyme Corporation | Amido-amine polymer compositions |
| AU2008206231A1 (en) * | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| JP2010519298A (ja) * | 2007-02-23 | 2010-06-03 | ゲンズイメ コーポレーション | アミンポリマー組成物 |
| EP2131820A1 (en) * | 2007-03-08 | 2009-12-16 | Genzyme Corporation | Sulfone polymer compositions |
| EP2152277A1 (en) * | 2007-04-27 | 2010-02-17 | Genzyme Corporation | Amido-amine dendrimer compositions |
| WO2009078958A1 (en) * | 2007-12-14 | 2009-06-25 | Genzyme Corporation | Coated pharmaceutical compositions |
| US20110142952A1 (en) * | 2008-06-20 | 2011-06-16 | Harris David J | Pharmaceutical Compositions |
| US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
| CA2812034C (en) | 2010-09-10 | 2018-10-23 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
| SI3287133T1 (sl) | 2013-06-05 | 2019-09-30 | Tricida Inc. | Polimeri, ki vežejo protone,za peroralno dajanje |
| LT3229816T (lt) | 2014-12-10 | 2020-05-25 | Tricida Inc. | Protoną prijungiantys polimerai, skirti peroraliniam įvedimui |
| WO2017193024A1 (en) | 2016-05-06 | 2017-11-09 | Tricida, Inc. | Hcl-binding compositions for and method of treating acid-base disorders |
| BR112019013364A2 (pt) | 2016-12-28 | 2020-04-14 | Fujifilm Corp | emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas |
| CN111225674A (zh) | 2017-10-16 | 2020-06-02 | 富士胶片株式会社 | 高磷血症治疗剂 |
| IL319146A (en) | 2017-11-03 | 2025-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| EP4164659B1 (en) * | 2021-08-24 | 2024-03-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Polymers, compositions and methods for treating hyperuricemia |
| EP4161534B1 (en) * | 2021-08-24 | 2024-11-06 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Polymers, compositions and methods for treating hyperuricemia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271191A (en) * | 1979-12-19 | 1981-06-02 | Pierre Fabre S.A. | Method of treating hyperuricemia and gout |
| DE3727082A1 (de) * | 1987-08-14 | 1989-02-23 | Goedecke Ag | Pharmazeutische zubereitungen zur behandlung der urolithiasis |
| EP0934352B1 (en) * | 1996-10-23 | 2007-05-02 | Dow Global Technologies Inc. | Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption |
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| WO2002085380A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for treating gout and reducing serum uric acid |
-
2002
- 2002-04-10 BR BR0209133-0A patent/BR0209133A/pt not_active IP Right Cessation
- 2002-04-10 CA CA002444347A patent/CA2444347A1/en not_active Abandoned
- 2002-04-10 DE DE60224052T patent/DE60224052T2/de not_active Expired - Lifetime
- 2002-04-10 EP EP02726732A patent/EP1416942B1/en not_active Expired - Lifetime
- 2002-04-10 AT AT02726732T patent/ATE380553T1/de not_active IP Right Cessation
- 2002-04-10 JP JP2002582954A patent/JP2004528332A/ja active Pending
- 2002-04-10 WO PCT/US2002/011492 patent/WO2002085381A1/en not_active Ceased
- 2002-04-10 MX MXPA03009571A patent/MXPA03009571A/es unknown
- 2002-04-17 US US10/125,685 patent/US20030039627A1/en not_active Abandoned
-
2007
- 2007-06-18 US US11/820,292 patent/US20080112918A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004528332A5 (https=) | ||
| JP2004535384A5 (https=) | ||
| JP2001521902A5 (https=) | ||
| JP2007517047A5 (https=) | ||
| CA2444046A1 (en) | Use of colesevelam in reducing serum glucose | |
| JP2004516314A5 (https=) | ||
| CA2481365A1 (en) | Occlusive composition comprising a poly (2-cyanoacrylate) monomer | |
| JP2004531544A5 (https=) | ||
| JP2005538035A5 (https=) | ||
| JP2004520473A5 (https=) | ||
| CN104548193A (zh) | 具有含不同水胶体成分的粘合剂层的分层粘合剂结构 | |
| JP2005508436A5 (https=) | ||
| JP2007530441A5 (https=) | ||
| JP2005506298A5 (https=) | ||
| JP2002501049A5 (https=) | ||
| JP2005532287A5 (https=) | ||
| JP2009502355A5 (https=) | ||
| JP2004526778A5 (https=) | ||
| JP2011515349A5 (https=) | ||
| JPH10192285A5 (https=) | ||
| JP2019211764A5 (https=) | ||
| RU2010153904A (ru) | Ниацин-содержащие композиции с модифицированным высвобождением | |
| JP2019508496A5 (https=) | ||
| JP2007537301A5 (https=) | ||
| JP2020518685A5 (https=) |